Please login to the form below

Not currently logged in
Email:
Password:

Pills to fight obesity available OTC

GSK's Alli will be available to adults with a body mass index (BMI) of 28 or over, over the counter this week

GlaxoSmithKline's (GSK) Alli (Orlistat) will be available to adults with a body mass index (BMI) of 28 or over, over the counter this week. It is claimed that users will be able to shed 3lb a week, equivalent to more than three stones over a four-month period.

Alli works by absorbing approximately 25 per cent of the fat from food, thereby preventing it being turned into extra pounds by the body. The undigested fat passes straight through the body, creating "an urgent need to go to the bathroom".

However, according to a report in the Telegraph, Gareth Williams, professor of medicine at the University of Bristol and the author of Obesity: Science To Practice, has said Alli's side-effects are so severe that "possibly few users will even finish their first pack, let alone buy a second".

More seriously, he added: "The drug may cause only a small and transient downward blip in the otherwise inexorable climb in weight."

"Selling anti-obesity drugs over the counter will perpetuate the myth that obesity can be fixed simply by popping a pill and could further undermine efforts to promote healthy living, which is the only long-term escape from obesity," Prof Williams wrote in the British Medical Journal.

Profession Williams cautioned that real-life weight loss may not be as dramatic as in clinical trials, which showed that adding Alli to a reduced calorie, lower fat diet can help people lose 50 per cent more fat than dieting alone.

Alli costs £1.60 a day and is a diluted version of the prescription-only drug Xenical.

20th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics